Literature DB >> 3891070

Transplantation of human basal cell carcinomas to athymic mice.

R E Grimwood, C A Johnson, C F Ferris, D B Mercill, J R Mellette, J C Huff.   

Abstract

Basal cell carcinomas (BCCs) obtained from 22 subjects undergoing microscopically controlled surgery were transplanted to 40 athymic (nude) mice. With no further immunosuppression of the mice, no tumor growth was noted in the first 14 attempts. When mice were further immunosuppressed with anti-lymphocyte serum (ALS) injections and by splenectomy, successful tumor growth was achieved in 15 of 22 mice by a subcutaneous implantation technique and in 1 of 4 by a superficial grafting technique. Transplanted BCC retained the morphology and basement membrane proteins typical of human BCC. As determined by autoradiography, 3H-thymidine was incorporated primarily in the peripheral palisaded cells of the transplanted tumor. Successful use of the athymic mouse model for study of human BCC requires use of mice further immunosuppressed by splenectomy and ALS, and the use of a subcutaneous implantation technique. With the use of this model, studies of the biology of human BCC may be possible.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891070     DOI: 10.1002/1097-0142(19850801)56:3<519::aid-cncr2820560319>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Ki-67 antigen expression and growth pattern of basal cell carcinomas.

Authors:  H P Baum; I Meurer; G Unteregger
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

2.  Immunohistochemical studies of basal cell carcinomas transplanted into nude mice.

Authors:  T H Löning; I C Mackenzie
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis.

Authors:  Grace Ying Wang; Po-Lin So; Lynn Wang; Eileen Libove; Joy Wang; Ervin H Epstein
Journal:  J Invest Dermatol       Date:  2011-08-11       Impact factor: 8.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.